Related Experiment Video

Updated: Mar 21, 2026

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

1.7K

Succinate metabolism: a new therapeutic target for myocardial reperfusion injury

Victoria R Pell1, Edward T Chouchani2, Christian Frezza3

  • 1Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Hills Road, Cambridge CB2 0QQ, UK.

Cardiovascular Research
|May 20, 2016
PubMed

Insights

Myocardial ischemia/reperfusion (IR) injury involves mitochondrial reactive oxygen species (ROS) production. This review explores how succinate accumulation during ischemia drives ROS, offering therapeutic targets for heart protection.

Area of Science:

  • Cardiovascular Research
  • Mitochondrial Metabolism
  • Ischemia-Reperfusion Injury

Background:

  • Myocardial ischemia/reperfusion (IR) injury is a leading cause of mortality with limited treatments.
  • Mitochondrial reactive oxygen species (ROS) are key mediators of IR-induced tissue damage.
  • The exact mechanisms of ROS production during reperfusion have been unclear.

Purpose of the Study:

  • To review the role of succinate in myocardial IR injury.
  • To elucidate the mechanism of succinate accumulation during ischemia and its role in ROS production.
  • To discuss therapeutic strategies targeting succinate metabolism for cardioprotection.

Main Methods:

  • Review of existing literature on myocardial IR injury and mitochondrial metabolism.
  • Focus on the role of the citric acid cycle intermediate, succinate.
  • Examination of reverse electron transport at Complex I as a ROS source.

Main Results:

  • Succinate accumulates during ischemia via a specific metabolic pathway.
  • Accumulated succinate drives ROS production at Complex I during reperfusion through reverse electron transport.
  • This mechanism provides a unifying model for various cardioprotective compounds.

Conclusions:

  • Succinate accumulation during ischemia is a critical driver of IR injury.
  • Targeting succinate metabolism offers a promising therapeutic strategy for reducing reperfusion injury.
  • Novel therapeutics could be developed to manipulate succinate levels for heart protection.
Keywords:
Ischaemia/reperfusionMitochondriaReactive oxygen speciesSuccinate

More Related Videos

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

9.8K
Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury07:23

Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury

Published on: March 7, 2022

7.5K

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
429
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
310
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
19.5K
The Electron Transport Chain01:30

The Electron Transport Chain

The electron transport chain or oxidative phosphorylation is an exothermic process in which free energy released during electron transfer reactions is coupled to ATP synthesis. This process is a significant source of energy in aerobic cells, and therefore inhibitors of the electron transport chain can be detrimental to the cell's metabolic processes.
Inhibitors of the electron transport chain
Rotenone, a widely used pesticide, prevents electron transfer from Fe-S cluster to ubiquinone or Q...
21.1K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
4.0K
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
706